NICE backs Lilly’s Taltz for axial spondyloarthritis
Drug has been cleared for use in patients whose condition is not controlled well enough with conventional therapy
Read More
Tag: taltz
Lilly bags expanded EU approval for Taltz
Taltz has been granted an additional indication for the treatment of patients across the full axSpA spectrum
Read More
Taltz trumps Tremfya in plaque psoriasis study
The drug met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study.
Read More
Positive results for Eli Lilly’s Taltz in late stage non-radiographic axial spondyloarthritis trial
Taltz is also approved to treat adults with moderate-to-severe plaque psoriasis.
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
Lilly’s Taltz hits goals in PhIII ankylosing spondylitis trial
Regulatory submissions for Lilly’s Taltz in ankylosing spondylitis (AS) are on the cards for later this year after the drug hit primary and secondary targets in a late-stage trial.
Read More
Lilly’s Taltz wins EU approval for psoriatic arthritis
Eli Lilly has been given a green light to market Taltz in the European Union as a treatment for psoriatic arthritis.
Read More
Lilly’s Taltz cleared to treat psoriatic arthritis
US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis.
Read More
NICE green light for Lilly’s psoriasis drug
Patients with plaque psoriasis should be able to get routine access to Eli Lilly’s Taltz on the NHS within the next three months if they meet certain eligibility criteria.
Read More
Scotland first UK nation to routinely offer HIV PrEP
Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside four other new therapies to be funded by the NHS.
Read More
NICE backs Lilly’s Taltz for psoriasis
Cost regulators for the NHS in England and Wales are endorsing Eli Lilly’s Taltz as a cost effective option for treating plaque psoriasis.
Read More
- Gobivaz approved across Europe as first Simponi biosimilar
- Poolbeg granted European patent for POLB 001
- TARA-002 shows strong early results in trial for paediatric lymphatic malformations
- Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
- Cellbyte raises $2.75m to slash drug launch timelines with AI
